



FOR IMMEDIATE RELEASE

**Merrimack Pharmaceuticals Enters into License Agreement with Selexis SA to
Use SURE Technology Platform for Cell Line Development
-- Merrimack will Use Selexis Technology for the Research, Development and
Manufacturing of Therapeutic Candidates --**

Geneva, Switzerland – May 30, 2006 – Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic proteins, announced today that it has entered into a non-exclusive R&D and manufacturing license agreement with Merrimack Pharmaceuticals, Inc. (“Merrimack”) under which Merrimack will have the rights to use Selexis’ SURE Technology Platform to research, develop and manufacture mammalian cell lines for protein therapeutic candidates.

“Selexis’ technology is a perfect fit for Merrimack’s philosophy of efficient drug discovery and development,” said Dr. Igor Fisch, CEO of Selexis.

Under the terms of the license agreement, Merrimack will have the right to internally use the SURE Technology Platform to develop mammalian cell lines for the research, development and manufacturing of Merrimack therapeutic candidates. The financial details of the agreement were not disclosed.

Selexis’ SURE Technology Platform, which includes the patented MARtech™, is a unique technology that improves the speed, yield and stability of production cell lines used for therapeutic protein manufacturing. Based on proprietary human MAR (Matrix Attachment Region), MARtech™ enables cell population generation in just four weeks (after transfection) and stable cell line development in 10 weeks (after transfection to first round of cell cloning). Additionally, MARtech™ has been found to significantly increase recombinant protein expression in mammalian cells in suspension and in serum-free up to 20 fold.

- more -

SELEXIS EUROPE
18 chemin des Aulx
1228 Plan-les-Ouates
Switzerland

T +41 (0)22 308 93 60
F +41 (0)22 308 93 61

SELEXIS USA
655, Montgomery St. STE 540
San Francisco, CA 94111
USA

T +1 415 273 51 41
F +1 415 837 32 04

“We believe that the SURE platform technology has the potential to help us to speed up the process of developing and manufacturing our innovative biopharmaceuticals” said Mark Moody, Ph.D., Director of Manufacturing Operations at Merrimack.

About Selexis

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services. Selexis offers comprehensive and rapid solutions for the development of stable, high yield mammalian cell lines used in recombinant protein manufacturing. The Company’s unique SURE cell line process, which includes Selexis’ forth generation patented MARtech™, reduces traditional cell line development (DHFR) from 12 months to 3 months (after transfection to isolating cell clones) without any change in the scale-up process. For more information please visit <http://www.selexis.com>

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis or with psoriasis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed in concert with leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. For additional information, please visit <http://www.merrimackpharma.com>.

Merrimack Pharmaceuticals Enters into License Agreement with Selexis SA

Page 3

This news release contains forward-looking statements that involve a number of known and unknown risks and uncertainties. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, we cannot assure you that we will be able to successfully develop or commercialize products based on our technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our joint ventures or our collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that our business strategy will be successful or that we will be able to carry out our plans for 2007.

MARtech™ is a trademark of Selexis, SA.

MEDIA CONTACT:

Robert Meister
602-953-1716
robert.meister@selexis.com

MORE INFORMATION:

EUROPE
Igor Fisch, Ph.D.
41 (0)22 308 93 60
igor.fisch@selexis.com

UNITED STATES
Cori Gorman, Ph.D., M.B.A.,
415-273-5141
cori.gorman@selexis.com

###